Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The price of Novavax, Inc (NASDAQ: NVAX) closed at $6.8 in the last session, down -1.31% from day before closing price of $6.89. In other words, the price has decreased by -$1.31 from its previous closing price. On the day, 2.68 million shares were traded. NVAX stock price reached its highest trading level at $6.895 during the session, while it also had its lowest trading level at $6.735.
Ratios:
We take a closer look at NVAX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.24 and its Current Ratio is at 2.27.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 19 ’25 when YOUNG JAMES F bought 10,000 shares for $7.59 per share.
YOUNG JAMES F bought 4,000 shares of NVAX for $24,406 on Apr 14 ’25. On Dec 31 ’24, another insider, YOUNG JAMES F, who serves as the Director of the company, sold 5,400 shares for $8.00 each. As a result, the insider received 43,200 and left with 51,760 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVAX now has a Market Capitalization of 1104993152 and an Enterprise Value of 593239168. As of this moment, Novavax,’s Price-to-Earnings (P/E) ratio for their current fiscal year is 3.84, and their Forward P/E ratio for the next fiscal year is 52.08. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.83. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.04. Its current Enterprise Value per Revenue stands at 0.557 whereas that against EBITDA is 1.313.
Stock Price History:
The Beta on a monthly basis for NVAX is 2.37, which has changed by -0.18654072 over the last 52 weeks, in comparison to a change of 0.13927746 over the same period for the S&P500. Over the past 52 weeks, NVAX has reached a high of $11.55, while it has fallen to a 52-week low of $5.01. The 50-Day Moving Average of the stock is -7.40%, while the 200-Day Moving Average is calculated to be -7.62%.
Shares Statistics:
According to the various share statistics, NVAX traded on average about 4.08M shares per day over the past 3-months and 3719070 shares per day over the past 10 days. A total of 162.47M shares are outstanding, with a floating share count of 154.79M. Insiders hold about 4.74% of the company’s shares, while institutions hold 60.66% stake in the company. Shares short for NVAX as of 1764288000 were 51861435 with a Short Ratio of 12.72, compared to 1761868800 on 48322992. Therefore, it implies a Short% of Shares Outstanding of 51861435 and a Short% of Float of 32.029998.
Earnings Estimates
As of right now, 7.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $0.0, with high estimates of $0.32 and low estimates of -$0.34.
Analysts are recommending an EPS of between $2.91 and $1.18 for the fiscal current year, implying an average EPS of $2.15. EPS for the following year is $0.26, with 8.0 analysts recommending between $3.87 and -$0.94.
Revenue Estimates
According to 8 analysts,. The current quarter’s revenue is expected to be $90.26M. It ranges from a high estimate of $167M to a low estimate of $71M. As of. The current estimate, Novavax, Inc’s year-ago sales were $88.31MFor the next quarter, 8 analysts are estimating revenue of $114.53M. There is a high estimate of $172.5M for the next quarter, whereas the lowest estimate is $58.9M.
A total of 9 analysts have provided revenue estimates for NVAX’s current fiscal year. The highest revenue estimate was $1.14B, while the lowest revenue estimate was $1.05B, resulting in an average revenue estimate of $1.06B. In the same quarter a year ago, actual revenue was $682.16MBased on 9 analysts’ estimates, the company’s revenue will be $459.72M in the next fiscal year. The high estimate is $1.13B and the low estimate is $249.69M.
